Results 161 to 170 of about 19,152,238 (244)

Current Advances of Treatments, Therapeutic Targets, Biomarkers, Novel Drugs, and Machine Learning for Hypopharyngeal Squamous Cell Carcinoma

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Hypopharyngeal squamous cell carcinoma (HSCC) is an aggressive subtype of head and neck squamous cell carcinoma with insidious onset, early metastasis, and dismal prognosis. Conventional multimodal therapy achieves limited survival benefit, highlighting an urgent need for refined precision strategies.
Ce Li, Rui Guan, Rui‐Jie Jiao, Zhi‐Jie Bi, Yang Fu, Yin Wang, Chen‐Yang Xu, Ye Qian, Ran Wei, Sheng‐Da Cao, Wen‐Ming Li, Dong‐Min Wei, Da‐Peng Lei   +12 more
wiley   +1 more source

Resistance to third-generation EGFR TKIs - what can be expected from the fourth-generation? [PDF]

Cancer Drug Resist
Dempke WCM, Fenchel K, Sullivan L, Reck M.   +3 more
europepmc   +1 more source

Umbilical Cord Blood–Derived Extracellular Vesicles Enhance Neurovascular Regeneration and Improve Erectile Function in a Mouse Model of Bilateral Cavernous Nerve Injury

Andrology, EarlyView.
ABSTRACT Background Erectile dysfunction (ED) secondary to cavernous nerve injury (CNI), such as that occurring after radical prostatectomy, remains a significant clinical challenge, particularly among patients who do not respond to phosphodiesterase Type 5 inhibitors (PDE5i).
Minh Nhat Vo, Guo Nan Yin, Fitri Rahma Fridayana, Yan Huang, Limanjaya Anita, Ju‐Hee Kang, Ji‐Kan Ryu   +6 more
wiley   +1 more source

Signaling Pathway-Biomarker Coupling for Precision Therapy in Rheumatoid Arthritis: Mechanistic Insights, Translational Bottlenecks, and Emerging Strategies. [PDF]

ACR Open Rheumatol
Meng S, Xing F, Luo Y, Li J, Ni Y, Zhang F, Xu H, Wang Y, Zhang W.   +8 more
europepmc   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source

Elucidating Therapeutic Targets in Hereditary Multicentric Carpotarsal Osteolysis FSGS. [PDF]

J Am Soc Nephrol
Gbadegesin RA, Lane BM.
europepmc   +1 more source

The potential for biased signalling in the P2Y receptor family of GPCRs

British Journal of Pharmacology, EarlyView.
The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk, Simon Pitchford, Graham Ladds   +2 more
wiley   +1 more source

The Phosphatidylinositol 3-Kinase (PI3K) Inhibitor Inavolisib Has Breast-cancer Synergy Combined With Recombinant Methioninase But Not on Normal Cells. [PDF]

In Vivo
Kim J, Han Q, Li S, Miyashi Y, Ishiguro T, Bouvet M, Hoffman RM.   +6 more
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

The Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective. [PDF]

Basic Clin Pharmacol Toxicol
Catakli D, Ozen-Basoglu O, Tuncgovde EB, Ozsarlak-Sozer G.   +3 more
europepmc   +1 more source